The North America Metastatic Cancer Drugs Market would witness market growth of 6.7% CAGR during the forecast period (2023-2030).
Metastatic cancer is treated with greater difficulty than early-stage cancer. Although most treatments focus on providing palliative care, metastatic cancer is treatable in some circumstances. The expenditure of R&D in the field of oncology has increased along with the frequency of disease and the length of life. In addition, several biopharmaceutical companies are attempting to enter the market and investing in the oncology field to satisfy the growing treatment needs of patients with metastatic cancer. These companies continue to pursue cost-effective oncology drugs with a high output level. Additionally, the emergence of precision medicine in the healthcare sector presents a chance for creating customized cancer treatments.
Lung, breast, prostate, and colorectal cancer are the four most common kinds of cancer. Additionally, the biopharmaceutical sector has experienced tremendous growth, which has led to the creation of several new, cutting-edge medications that can effectively target cancer cells while causing no harm to healthy cells. The market is expanding rapidly due to the growing public awareness of the availability of numerous cutting-edge treatments to treat cancer.
As per National Cancer Institute, the number of new cancer cases expected to be diagnosed in the US in 2020 is 1,806,590, while the number of cancer-related deaths is predicted to be 606,520. In 2020, it is anticipated that 43% of all cancer diagnoses in men will be prostate, lung, and colorectal. Breast, lung, and colorectal cancers are the three most prevalent cancers in women, and in 2020, new cancer diagnoses in women are expected to account for 50% of all new cancer diagnoses. Men are more likely than women to die from cancer (189.5 per 100,000 men and 135.7 per 100,000 women).
There were reportedly 16.9 million cancer survivors in the United States as of January 2019. By 2030, the number of cancer survivors is expected to reach 22,2 million. One thousand seven hundred thirty cancer-related deaths and 16,850 new cancer diagnoses are expected in children and teenagers aged 0 to 19 in 2020. In Canada, 233,900 new instances of cancer and 85 100 cancer-related deaths are anticipated in 2022. As a result of the rising cases of cancer across the region, the market is estimated to grow at a steady pace.
The US market dominated the North America Metastatic Cancer Drugs Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $36,469.5 million by 2030. The Canada market is experiencing a CAGR of 9.1% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 8.1% during (2023 - 2030).
Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Providers. Based on Indication, the market is segmented into Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma & Others. Based on Therapy, the market is segmented into Targeted Therapy, Immunotherapy, Hormonal Therapy and Chemotherapy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Metastatic Cancer Drugs Market is Projected to reach USD 115.6 Billion by 2030, at a CAGR of 7.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bristol Myers Squibb Company, Merck & Co., Inc., AstraZeneca PLC, Novartis AG, Eli Lilly And Company, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen, Inc. and Sanofi S.A.
Scope of the Study
Market Segments Covered in the Report:
By Distribution Channel
- Hospital Pharmacies
- Drug Store & Retail Pharmacies
- Online Providers
By Indication
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Colorectal Cancer
- Melanoma & Others
By Therapy
- Targeted Therapy
- Immunotherapy
- Hormonal Therapy
- Chemotherapy
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Bristol Myers Squibb Company
- Merck & Co., Inc.
- AstraZeneca PLC
- Novartis AG
- Eli Lilly And Company
- Pfizer, Inc.
- F.Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Amgen, Inc.
- Sanofi S.A.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Metastatic Cancer Drugs Market, by Distribution Channel
1.4.2 North America Metastatic Cancer Drugs Market, by Indication
1.4.3 North America Metastatic Cancer Drugs Market, by Therapy
1.4.4 North America Metastatic Cancer Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Approvals & Trials
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements: 2019, Jul – 2023, Apr) Leading Players
4.4 Porter’s Five Forces Analysis
Chapter 5. North America Metastatic Cancer Drugs Market by Distribution Channel
5.1 North America Hospital Pharmacies Market by Country
5.2 North America Drug Store & Retail Pharmacies Market by Country
5.3 North America Online Providers Market by Country
Chapter 6. North America Metastatic Cancer Drugs Market by Indication
6.1 North America Breast Cancer Market by Country
6.2 North America Lung Cancer Market by Country
6.3 North America Prostate Cancer Market by Country
6.4 North America Colorectal Cancer Market by Country
6.5 North America Melanoma & Others Market by Country
Chapter 7. North America Metastatic Cancer Drugs Market by Therapy
7.1 North America Targeted Therapy Market by Country
7.2 North America Immunotherapy Market by Country
7.3 North America Hormonal Therapy Market by Country
7.4 North America Chemotherapy Market by Country
Chapter 8. North America Metastatic Cancer Drugs Market by Country
8.1 US Metastatic Cancer Drugs Market
8.1.1 US Metastatic Cancer Drugs Market by Distribution Channel
8.1.2 US Metastatic Cancer Drugs Market by Indication
8.1.3 US Metastatic Cancer Drugs Market by Therapy
8.2 Canada Metastatic Cancer Drugs Market
8.2.1 Canada Metastatic Cancer Drugs Market by Distribution Channel
8.2.2 Canada Metastatic Cancer Drugs Market by Indication
8.2.3 Canada Metastatic Cancer Drugs Market by Therapy
8.3 Mexico Metastatic Cancer Drugs Market
8.3.1 Mexico Metastatic Cancer Drugs Market by Distribution Channel
8.3.2 Mexico Metastatic Cancer Drugs Market by Indication
8.3.3 Mexico Metastatic Cancer Drugs Market by Therapy
8.4 Rest of North America Metastatic Cancer Drugs Market
8.4.1 Rest of North America Metastatic Cancer Drugs Market by Distribution Channel
8.4.2 Rest of North America Metastatic Cancer Drugs Market by Indication
8.4.3 Rest of North America Metastatic Cancer Drugs Market by Therapy
Chapter 9. Company Profiles
9.1 Bristol Myers Squibb Company
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 Merck & Co., Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.6 SWOT Analysis
9.3 AstraZeneca PLC
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expenses
9.3.5 SWOT Analysis
9.4 Novartis AG
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.4.5.1 Partnerships, Collaborations, and Agreements:
9.4.6 SWOT Analysis
9.5 Eli Lilly And Company
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Partnerships, Collaborations, and Agreements:
9.5.6 SWOT Analysis
9.6 Pfizer, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional & Segmental Analysis
9.6.4 Research & Development Expense
9.6.5 Recent strategies and developments:
9.6.5.1 Partnerships, Collaborations, and Agreements:
9.6.5.2 Acquisition and Mergers:
9.6.6 SWOT Analysis
9.7 F. Hoffmann-La Roche Ltd.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Product Launches and Product Expansions:
9.7.5.3 Trials & Approvals:
9.7.6 SWOT Analysis
9.8 Johnson & Johnson
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental &Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Acquisition and Mergers:
9.8.6 SWOT Analysis
9.9 Amgen, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional Analysis
9.9.4 Research & Development Expenses
9.9.5 SWOT Analysis
9.10. Sanofi S.A.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
9.10.5 Recent strategies and developments:
9.10.5.1 Partnerships, Collaborations, and Agreements:
9.10.6 SWOT Analysis
TABLE 1 North America Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 2 North America Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Metastatic Cancer Drugs Market
TABLE 4 Product Launches And Product Expansions– Metastatic Cancer Drugs Market
TABLE 5 Acquisition and Mergers– Metastatic Cancer Drugs Market
TABLE 6 Approvals & Trials– Metastatic Cancer Drugs Market
TABLE 7 North America Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 8 North America Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 9 North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 10 North America Hospital Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 11 North America Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 12 North America Drug Store & Retail Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 13 North America Online Providers Market by Country, 2019 - 2022, USD Million
TABLE 14 North America Online Providers Market by Country, 2023 - 2030, USD Million
TABLE 15 North America Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 16 North America Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 17 North America Breast Cancer Market by Country, 2019 - 2022, USD Million
TABLE 18 North America Breast Cancer Market by Country, 2023 - 2030, USD Million
TABLE 19 North America Lung Cancer Market by Country, 2019 - 2022, USD Million
TABLE 20 North America Lung Cancer Market by Country, 2023 - 2030, USD Million
TABLE 21 North America Prostate Cancer Market by Country, 2019 - 2022, USD Million
TABLE 22 North America Prostate Cancer Market by Country, 2023 - 2030, USD Million
TABLE 23 North America Colorectal Cancer Market by Country, 2019 - 2022, USD Million
TABLE 24 North America Colorectal Cancer Market by Country, 2023 - 2030, USD Million
TABLE 25 North America Melanoma & Others Market by Country, 2019 - 2022, USD Million
TABLE 26 North America Melanoma & Others Market by Country, 2023 - 2030, USD Million
TABLE 27 North America Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 28 North America Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 29 North America Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 30 North America Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 31 North America Immunotherapy Market by Country, 2019 - 2022, USD Million
TABLE 32 North America Immunotherapy Market by Country, 2023 - 2030, USD Million
TABLE 33 North America Hormonal Therapy Market by Country, 2019 - 2022, USD Million
TABLE 34 North America Hormonal Therapy Market by Country, 2023 - 2030, USD Million
TABLE 35 North America Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 36 North America Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 37 North America Metastatic Cancer Drugs Market by Country, 2019 - 2022, USD Million
TABLE 38 North America Metastatic Cancer Drugs Market by Country, 2023 - 2030, USD Million
TABLE 39 US Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 40 US Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 41 US Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 42 US Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 43 US Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 44 US Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 45 US Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 46 US Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 47 Canada Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 48 Canada Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 49 Canada Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 50 Canada Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 51 Canada Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 52 Canada Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 53 Canada Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 54 Canada Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 55 Mexico Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 56 Mexico Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 57 Mexico Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 58 Mexico Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 59 Mexico Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 60 Mexico Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 61 Mexico Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 62 Mexico Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 63 Rest of North America Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 64 Rest of North America Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 65 Rest of North America Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 66 Rest of North America Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 67 Rest of North America Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 68 Rest of North America Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 69 Rest of North America Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 70 Rest of North America Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 71 Key Information – Bristol Myers Squibb Company
TABLE 72 KEY INFORMATION - Merck & Co., Inc.
TABLE 73 KEY INFORMATION – AstraZeneca PLC
TABLE 74 Key Information – Novartis AG
TABLE 75 Key Information – Eli Lilly And Company
TABLE 76 Key Information – Pfizer, Inc.
TABLE 77 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 78 Key Information – Johnson & Johnson
TABLE 79 Key Information – Amgen, Inc.
TABLE 80 Key Information – Sanofi S.A.
List of Figures
FIG 1 Methodology for the research
FIG 2 North America Metastatic Cancer Drugs Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Metastatic Cancer Drugs Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: (Partnerships, Collaborations, and Agreements: 2019, Jul – 2023, Apr) Leading Players
FIG 7 Porter’s Five Forces Analysis - Metastatic Cancer Drugs Market
FIG 8 North America Metastatic Cancer Drugs Market share by Distribution Channel, 2022
FIG 9 North America Metastatic Cancer Drugs Market share by Distribution Channel, 2030
FIG 10 North America Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2030, USD Million
FIG 11 North America Metastatic Cancer Drugs Market share by Indication, 2022
FIG 12 North America Metastatic Cancer Drugs Market share by Indication, 2030
FIG 13 North America Metastatic Cancer Drugs Market by Indication, 2019 - 2030, USD Million
FIG 14 North America Metastatic Cancer Drugs Market share by Therapy, 2022
FIG 15 North America Metastatic Cancer Drugs Market share by Therapy, 2030
FIG 16 North America Metastatic Cancer Drugs Market by Therapy, 2019 - 2030, USD Million
FIG 17 North America Metastatic Cancer Drugs Market share by Country, 2022
FIG 18 North America Metastatic Cancer Drugs Market share by Country, 2030
FIG 19 North America Metastatic Cancer Drugs Market by Country, 2019 - 2030, USD Million
FIG 20 SWOT Analysis: Bristol Myers Squibb Company
FIG 21 Swot Analysis: Merck & Co., Inc.
FIG 22 Swot Analysis: AstraZeneca PLC
FIG 23 SWOT Analysis: Novartis AG
FIG 24 Swot Analysis: Eli Lilly And Company
FIG 25 Recent strategies and developments: Pfizer, Inc.
FIG 26 Swot Analysis: Pfizer, Inc.
FIG 27 Recent strategies and developments: F. Hoffmann-La Roche Ltd.
FIG 28 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 29 Swot Analysis: Johnson & Johnson
FIG 30 Swot Analysis: Amgen, Inc.
FIG 31 Swot Analysis: Sanofi S.A.